DOCSLIB.ORG

STELARA INJECTION Ustekinumab (Rmc)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
STELARA INJECTION Ustekinumab (Rmc) ® STELARA INJECTION Ustekinumab (rmc) Consumer Medicine Information What is in this leaflet monoclonal antibody. Do not use STELARA if the Monoclonal antibodies are packaging is torn or shows signs This leaflet answers some proteins that recognise and bind to of tampering, or if the liquid is common questions about other unique proteins. discoloured or cloudy. STELARA (pronounced stel-ahr- Ustekinumab blocks the action of Do not use STELARA beyond the uh). It does not contain all the two proteins in your body called expiry date (month and year) available information. It does not interleukin 12 (IL-12) and printed on the pack. take the place of talking to your interleukin 23 (IL-23). IL-12 and Do not use STELARA if you doctor, nurse or pharmacist. IL-23 are made by your body's know or think that it may have All medicines have risks and immune system. In people with been exposed to extreme benefits. Your doctor has weighed psoriasis, psoriatic arthritis, temperatures (such as being the risks of you using STELARA Crohn’s disease or ulcerative accidentally frozen or heated). against the benefits this medicine colitis, IL-12 and IL-23 can cause is expected to have for you. their immune system to attack Before you start to use it normal healthy parts of their body If you have any concerns about like the skin and nails. You must tell your doctor about all using STELARA, ask your doctor Ustekinumab can block IL-12 and of your medical conditions before or pharmacist. IL-23 from causing the immune each treatment, including if you: It is important that you read this system to attack the skin and nails. • have any kind of infection, leaflet. Keep this leaflet with your Ask your doctor if you have any even if it is very minor medicine. You may need to read it questions about why this medicine • have an infection that won't go again. has been prescribed for you. Your away or a history of infection doctor may have prescribed it for that keeps coming back another reason. • have had TB (tuberculosis), or This medicine is available only if you have recently been near What STELARA is with a doctor’s prescription. anyone who might have TB used for • have or have had any type of cancer STELARA is a prescription • have any new or changing medicine that is used to treat: Before you use STELARA lesions within psoriasis areas • adults with moderate to severe or on normal skin plaque psoriasis that is chronic • When you must not use it have recently received or are (doesn’t go away), scheduled to receive a • adults with active psoriatic Do not use STELARA if you vaccine. Patients receiving arthritis, an inflammatory have an allergy to: STELARA should not receive disease of the joints that is • ustekinumab, the active live vaccines. Tell your usually accompanied by ingredient in the medicine doctor if anyone in your house psoriasis, • any of the other ingredients in needs a vaccine. The viruses in some vaccines can spread to • adults with moderately to STELARA. See Product severely active Crohn’s Description at the end of this people with a weakened Disease, an inflammatory leaflet for a list of ingredients. immune system, and can cause serious problems disease of the bowel Symptoms of an allergic reaction • are receiving allergy • may include rash, itching or adults with moderate to severe immunotherapy. ulcerative colitis, an hives on the skin, shortness of • inflammatory disease of the breath, wheezing or difficulty are pregnant, planning to bowel. breathing, swelling of the face, become pregnant, or breastfeeding. Adequate lips, tongue or other parts of the STELARA contains the active contraception should be used ingredient ustekinumab, a body. to avoid falling pregnant. STELARA (200603) ACMI NZ 1 CCDS191010 STELARA should only be you may be able to administer • if you know, or think that it used during a pregnancy if STELARA under the skin yourself may have been exposed to needed. Women who are if you wish, after proper training in extreme temperatures (such as breastfeeding should talk to injection technique. (See being accidentally frozen or their doctor about whether or Injecting STELARA under the heated). not to use STELARA. skin yourself.) Do not shake STELARA at any • have an allergy to latex. It is important to remember that time. Prolonged vigorous shaking Your doctor will examine you for the first dose of STELARA for the may damage the product. If tuberculosis (TB). If your doctor treatment of Crohn’s Disease or STELARA has been shaken feels that you are at risk for TB, ulcerative colitis vigorously, don’t use it. you may be treated with medicine (intravenous infusion) will always STELARA is not to be mixed with for TB before you begin treatment be administered by your healthcare other liquids for injection. with STELARA and during provider. treatment with STELARA. How to inject STELARA from a pre-filled syringe If you have not told your doctor or How much to use pharmacist about any of the above, • Your doctor will determine the To reduce the risk of accidental tell them before you start using or correct dose of STELARA for needle stick injuries to users, each are given STELARA. you and how often you should pre-filled syringe is equipped with receive it. Make sure to a needle guard that is Taking other medicines discuss with your doctor when automatically activated to cover Tell your doctor or pharmacist if you will receive injections and the needle after complete delivery you are taking any other to come in for all your of the syringe content. medicines, including medicines scheduled follow-up 1. PREPARING FOR PRE- you can buy without a prescription appointments. FILLED SYRINGE USE from a pharmacy, supermarket or health food shop. Injecting STELARA under the skin yourself Your healthcare provider may decide that it is right for you or Take the syringe(s) out of the your caregiver to learn how to Using STELARA refrigerator. Make sure that it is inject STELARA under the skin the right dose. If your dose is 45 For the treatment of psoriasis or (subcutaneously) yourself. If you mg you will receive one 45 mg psoriatic arthritis STELARA is would like to self-inject syringe. If your dose is 90 mg, given by injection just under the STELARA under your skin, you you will receive two 45 mg skin (subcutaneously). must be trained by a healthcare syringes. If you receive two 45 professional to prepare an For the treatment of Crohn’s mg syringes for a 90 mg dose, you injection and give it to yourself. If Disease or ulcerative colitis, the will need to give yourself two you have not been trained, please first dose of STELARA will be injections one right after the other. contact your healthcare provider to given by an intravenous infusion, Check with your healthcare schedule a training session. Call which means that the medicine provider. will be given to you through a your healthcare provider if you needle placed in a vein. After this have any questions about giving Check Expiration Date starting dose, all future doses of yourself an injection. Open the box and remove the STELARA are given by injection STELARA is given alone and not syringe. Check the expiration date just under the skin mixed with other liquids for on the pre-filled syringe and the (subcutaneously). injection. label of the box. If the expiration date has passed, don’t use it. All STELARA injections are for STELARA should not be used: Check Solution in Syringe single use in one patient only. • after the expiry date on the Hold the pre-filled syringe with STELARA is intended for use label; the covered needle pointing under the guidance and upward. Make sure the syringe is • if the seal is broken; supervision of your doctor. When not damaged. Look at the solution you start treatment, STELARA • if the liquid is discoloured, or liquid in the vial to make sure may be injected by your healthcare cloudy or you can see other that it is not cloudy and not frozen. particulate matter floating in provider. If your doctor Assemble Additional Supplies determines that it is appropriate, it; STELARA (200603) ACMI NZ 2 CCDS191010 Assemble the additional supplies You may also see a drop of liquid Immediately dispose of the empty you will need for your injection. at the end of the needle – this is syringe into the sharps container. These include an antiseptic wipe, a normal. Do not touch the needle For your safety and health and for cotton ball or gauze, and a sharps or allow it to touch any surface. the safety of others, needles and container for syringe disposal. Note: The needle cover should syringes must NEVER be re-used. DO NOT remove the needle cover NOT be removed until you are Dispose of sharps container from the pre-filled syringe. ready to inject the dose. Do not according to your local DO NOT pull back on the plunger use the syringe if it is dropped regulations. See ‘After using head at any time. without the needle cover in place. STELARA - Disposal’. If you drop the syringe without the Use a Cotton Ball or Gauze 2. CHOOSING AND needle cover in place, please There may be a small amount of PREPARING THE contact your healthcare provider blood or liquid at the injection site, INJECTION SITE for assistance. which is normal. You can press a cotton ball or gauze over the Choose the Injection Site* injection site and hold for 10 Good sites are the top of the thigh 4.
Load more

Recommended publications
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Biological Therapies for Atopic Dermatitis: an Update (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 1061-1067, 2019 Biological therapies for atopic dermatitis: An update (Review) DIANA DELEANU1-3 and IRENA NEDELEA1,2 1Allergology and Immunology Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400058 Cluj-Napoca; Departments of 2Allergy and 3Internal Medicine, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania Received July 6, 2018; Accepted August 22, 2018 DOI: 10.3892/etm.2018.6989 Abstract. Severe atopic dermatitis, which affects both adults in low-income countries (3). Furthermore, the past decades and children, is a debilitating disorder with a significant decline brought a 2-3-fold increase in prevalence in industrialized of patients' quality of life. Although aetiopathogenic factors countries (3). Generally AD onset is in early childhood, as are currently a topic of study and interpretation, the main one of the first steps of the ‘atopic march’, which describes the features of atopic eczema are skin barrier disturbance and natural history of atopic manifestations, and it is character- immune dysregulation. Severe refractory disease that fails to ized by xerotic skin and acute flare-ups of intensely pruritic improve with conventional therapy may benefit from biologic eczematous lesions (4). Recent studies recognize a predilection therapy. Progress in understanding immunopathology of atopic of AD for persistence in adulthood, with a lifetime prevalence dermatitis have allowed identification of therapeutic molecular accounting for 34.1% (5). Early onset, allergic rhinitis and targets in the field of biological therapy. We reviewed the hand eczema in childhood are high-risk factors for persistent different biological treatments with a focus on novel targeted AD (5).
    [Show full text]
  • Anticorps FR-EN 110X90.Indd
    MONOCLONAL ANTIBODIES and Fc fusion proteins for therapeutic use DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION SOLID TUMORS RHUMATOLOGY PNEUMOLOGY Lung cancer bevacizumab Rheumatoid arthritis etanercept Allergic asthma omalizumab nivolumab infliximab Severe eosinophilic asthma mepolizumab necitumumab adalimumab reslizumab atezolizumab rituximab Colorectal cancer bevacizumab abatacept TRANSPLANTATION cetuximab tocilizumab Transplant rejection basiliximab panitumumab certolizumab pegol belatacept aflibercept golimumab Graft versus host disease inolimomab Bladder cancer atezolizumab Psoriatic arthritis etanercept Breast cancer trastuzumab adalimumab OPHTALMOLOGY bevacizumab infliximab Age related macular ranibizumab pertuzumab golimumab degeneration aflibercept trastuzumab entansine ustekinumab bevacizumab Gastric cancer trastuzumab certolizumab pegol Macular edema ranibizumab ramucirumab secukinumab aflibercept Head and neck cancer cetuximab Ankylosing spondylitis infliximab Myopic choroidal ranibizumab Ovarian cancer bevacizumab etanercept neovascularization aflibercept Fallopian tube cancer bevacizumab adalimumab Cervical cancer bevacizumab golimumab HAEMOSTASIS AND THROMBOSIS Kidney cancer bevacizumab certolizumab pegol nivolumab secukinumab Haemophilia A efmoroctocog α Melanoma ipilimumab Juvenile arthritis etanercept Haemophilia B eftrenonacog α nivolumab adalimumab Reversal of dabigatran idarucizumab Idiopathic thrombocytopenic pembrolizumab abatacept romiplostim Neuroblastoma dinutuximab tocilizumab purpura Malignant
    [Show full text]
  • Asthma Agents
    APPROVED PA Criteria Initial Approval Date: July 10, 2019 Revised Date: January 20, 2021 CRITERIA FOR PRIOR AUTHORIZATION Asthma Agents BILLING CODE TYPE For drug coverage and provider type information, see the KMAP Reference Codes webpage. MANUAL GUIDELINES Prior authorization will be required for all current and future dose forms available. All medication-specific criteria, including drug-specific indication, age, and dose for each agent is defined in Table 1 below. Benralizumab (Fasenra®) Dupilumab (Dupixent®) Mepolizumab (Nucala®) Omalizumab (Xolair®) Reslizumab (Cinqair®) GENERAL CRITERIA FOR INITIAL PRIOR AUTHORIZATION: (must meet all of the following) • Must be approved for the indication, age, and not exceed dosing limits listed in Table 1. • Must be prescribed by or in consultation with a pulmonologist, allergist, or immunologist.1,2 • For all agents listed, the preferred PDL drug, which treats the PA indication, is required unless the patient meets the non-preferred PDL PA criteria. • Must have experienced ≥ 2 exacerbations within the last 12 months despite meeting all of the following (exacerbation is defined as requiring the use of oral/systemic corticosteroids, urgent care/hospital admission, or intubation: o Patient adherence to two long-term controller medications, including a high-dose inhaled corticosteroid 1,2 (ICS) and a long-acting beta2-agonist (LABA) listed in Table 2. ▪ Combination ICS/LABA and ICS/LABA/LAMA products meet the requirement of two controller medications. o Patient must have had an adequate trial (at least 90 consecutive days) of a leukotriene modifier or a long-acting muscarinic antagonist (LAMA) as a third long-term controller medication listed in Table 2.
    [Show full text]
  • Cimzia (Certolizumab Pegol) AHM
    Cimzia (Certolizumab Pegol) AHM Clinical Indications • Cimzia (Certolizumab Pegol) is considered medically necessary for adult members 18 years of age or older with moderately-to-severely active disease when ALL of the following conditions are met o Moderately-to-severely active Crohn's disease as manifested by 1 or more of the following . Diarrhea . Abdominal pain . Bleeding . Weight loss . Perianal disease . Internal fistulae . Intestinal obstruction . Megacolon . Extra-intestinal manifestations: arthritis or spondylitis o Crohn's disease has remained active despite treatment with 1 or more of the following . Corticosteroids . 6-mercaptopurine/azathioprine • Certollizumab pegol (see note) is considered medically necessary for persons with active psoriatic arthritis who meet criteria in Psoriasis and Psoriatic Arthritis: Biological Therapies. • Cimzia, (Certolizumab Pegol), alone or in combination with methotrexate (MTX), is considered medically necessary for the treatment of adult members 18 years of age or older with moderately-to-severely active rheumatoid arthritis (RA). • Cimzia (Certolizumab pegol is considered medically necessary for reducing signs and symptoms of members with active ankylosing spondylitis who have an inadequate response to 2 or more NSAIDs. • Cimzia (Certolizumab Pegol) is considered investigational for all other indications (e.g.,ocular inflammation/uveitis; not an all-inclusive list) because its effectiveness for indications other than the ones listed above has not been established. Notes • There are several brands of targeted immune modulators on the market. There is a lack of reliable evidence that any one brand of targeted immune modulator is superior to other brands for medically necessary indications. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Simponi Aria (golimumab intravneous), and Stelara (ustekinumab) brands of targeted immune modulators ("least cost brands of targeted immune modulators") are less costly to the plan.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Immunology of Il-12: an Update on Functional Activities and Implications for Disease
    EXCLI Journal 2020;19:1563-1589 – ISSN 1611-2156 Received: November 13, 2020, accepted: December 07, 2020, published: December 11, 2020 Review article: IMMUNOLOGY OF IL-12: AN UPDATE ON FUNCTIONAL ACTIVITIES AND IMPLICATIONS FOR DISEASE Karen A.-M. Ullrich#1, Lisa Lou Schulze#1, Eva-Maria Paap1, Tanja M. Müller1, Markus F. Neurath1, Sebastian Zundler1,* # Shared first authorship 1 Department of Medicine and Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Friedrich-Alexander- University Erlangen-Nuremberg, Germany * Corresponding author: Dr. med. Sebastian Zundler, Department of Medicine and University Hospital Erlangen, Ulmenweg 18, D-91054 Erlangen, Germany, Phone: 09131/85-35000, E-mail: [email protected] http://dx.doi.org/10.17179/excli2020-3104 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). ABSTRACT As its first identified member, Interleukin-12 (IL-12) named a whole family of cytokines. In response to pathogens, the heterodimeric protein, consisting of the two subunits p35 and p40, is secreted by phagocytic cells. Binding of IL-12 to the IL-12 receptor (IL-12R) on T and natural killer (NK) cells leads to signaling via signal transducer and activator of transcription 4 (STAT4) and subsequent interferon gamma (IFN-γ) production and secretion. Signaling downstream of IFN-γ includes activation of T-box transcription factor TBX21 (Tbet) and induces pro-inflamma- tory functions of T helper 1 (TH1) cells, thereby linking innate and adaptive immune responses. Initial views on the role of IL-12 and clinical efforts to translate them into therapeutic approaches had to be re-interpreted following the discovery of other members of the IL-12 family, such as IL-23, sharing a subunit with IL-12.
    [Show full text]
  • What's New in Eczema Management
    What’s New in Eczema Management: Practice Pearls for the Family Physician This educational activity is jointly provided by the North Carolina Academy of Family Physicians (NCAFP) and Spire Learning. This activity is supported by an educational grant from Pfizer Inc. What’s New in Eczema Management: Practice Pearls for the Family Physician PROGRAM OVERVIEW This live meeting series will address the latest in the care and management of pediatric and adult dermatitis as well as strategies to individualize treatment. TARGET AUDIENCE Family physicians LEARNING OBJECTIVES At the conclusion of this live activity, family physicians should be better able to: • Recognize the clinical features and characteristic age distribution patterns of atopic dermatitis (AD) • Describe the role of skin barrier dysfunction, immune dysregulation, and environmental factors in the pathogenesis of AD • Individualize AD management regimens according to age, location, disease severity, response to treatment, and quality-of-life (QOL) concerns • Educate patients and families about the safe and appropriate use of skin-directed therapies for the treatment of AD ACCREDITATION AND DISCLAIMER STATEMENTS This live activity, What’s New in Eczema Management: Practice Pearls for the Family Physician has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AMA/AAFP Equivalency: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Monoclonal Antibodies As Neurological Therapeutics
    pharmaceuticals Review Monoclonal Antibodies as Neurological Therapeutics Panagiotis Gklinos 1 , Miranta Papadopoulou 2, Vid Stanulovic 3, Dimos D. Mitsikostas 4 and Dimitrios Papadopoulos 5,6,* 1 Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece; [email protected] 2 Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece; [email protected] 3 Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France; vid.stanulovic@sanofi.com 4 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece; [email protected] 5 Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece 6 Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece * Correspondence: [email protected] Abstract: Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysio- logical mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these
    [Show full text]
  • Soluble Ligands As Drug Targets
    REVIEWS Soluble ligands as drug targets Misty M. Attwood 1, Jörgen Jonsson1, Mathias Rask- Andersen 2 and Helgi B. Schiöth 1,3 ✉ Abstract | Historically, the main classes of drug targets have been receptors, enzymes, ion channels and transporters. However, owing largely to the rise of antibody- based therapies in the past two decades, soluble protein ligands such as inflammatory cytokines have become an increasingly important class of drug targets. In this Review, we analyse drugs targeting ligands that have reached clinical development at some point since 1992. We identify 291 drugs that target 99 unique ligands, and we discuss trends in the characteristics of the ligands, drugs and indications for which they have been tested. In the last 5 years, the number of ligand-targeting drugs approved by the FDA has doubled to 34, while the number of clinically validated ligand targets has doubled to 22. Cytokines and growth factors are the predominant types of targeted ligands (70%), and inflammation and autoimmune disorders, cancer and ophthalmological diseases are the top therapeutic areas for both approved agents and agents in clinical studies, reflecting the central role of cytokine and/or growth factor pathways in such diseases. Drug targets In the twentieth century, drug discovery largely involved far more challenging to achieve with small- molecule Pharmacological targets, such the identification of small molecules that exert their drugs. Protein ligands have been successfully targeted as proteins, that mediate the therapeutic effects by interacting with the binding sites by many drugs since the first FDA approval of the desired therapeutic effect of of endogenous small- molecule ligands such as neuro- ligand- targeting agents etanercept and infliximab in a drug.
    [Show full text]